Replies to post #110559 on Biotech Values

[jb_118]

They also say it's unclear whether physicians and patients will embrace biosimilar drugs, given that the complexity of producing such medicines could raise substantial safety issues.

Understanding they're quite different scenarios, but people were saying the same thing about generic lovenox. If the price is right, the use of biosimilars will ramp up fairly quickly once approved unless and until a major safety issue is seen.